Skip to main content

Treatment Clinical Trials for Acute Myeloid Leukemia (AML)

Review the acute myeloid leukemia (aml) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 305

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
2 Step ATG with Preparative Chemotherapy and Methotrexate for the Prevention of Acute GVHD for Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant for Hematopoietic Disorders
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Hyperbaric Oxygen Therapy to Improve Engraftment Following Umbilical Cord Blood Stem Cell Transplantation in Patients with Blood and Lymph Node Cancer
Status: Active
Location: University of Rochester, Rochester, New York
Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Standard-of-Care Reduced-Intensity Conditioning with Total Body Irradiation for the Treatment of Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Bortezomib in Combination with CPX-351 for the Treatment of Newly-Diagnosed TP53- Mutated Acute Myeloid Leukemia
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Decitabine and Venetoclax for Maintenance Treatment in Patients with AML and MDS After Donor Stem Cell Transplant
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Investigating Novel Therapies for the Treatment of Acute Myeloid Leukemia Patients with Rising Measurable Residual Disease and/or Morphological Relapse, ALLG AMLM26 INTERCEPT Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Momelotinib in Combination with Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Universal Donor Natural Killer Cells for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, KARMA Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Decitabine/Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tagraxofusp and Combination Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Decitabine and Venetoclax in Combination with Olutasidenib for the Treatment of Patients with Newly Diagnosed, Recurrent or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nadunolimab and Azacitidine With or Without Venetoclax for the Treatment of Patients with Myelodysplastic Syndrome or Relapsed or Refractory Acute Myelogenous Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas